The clinical brain
medicine forgot to build.

Modern metabolic care generates more data than any single visit can hold — lab results, body composition, medication adherence, wearable and nutrition signals, all scattered across systems that rarely speak to each other.

Longova's software sits alongside the treating clinician and turns that scattered data into a clear, continuous picture. It is designed to help clinicians see the whole patient, and to help the people who study and pay for care understand how patients actually do on therapy over time.

The principle we build on

Everything Longova does rests on a single line: Longova informs, the doctor decides. The platform contextualizes and synthesizes to support the clinician's judgment — it does not diagnose or prescribe. That boundary is deliberate, and it shapes both the product and how the company positions itself with regulators.

Who it serves

Longova is offered to clinics, and is designed to extend to pharmaceutical and payer partners who need real-world evidence on how patients do on therapy over time — particularly the question of who stays on treatment and why, which is where most of the real-world value in metabolic medicine is won or lost.

Why it matters

In metabolic medicine, the gap between a therapy's potential and its real-world result is rarely the drug. It is everything that happens between the visits: the symptoms that go unmanaged, the early loss of momentum, the quiet drift off treatment. Longova is built to make that in-between period visible, so it can be acted on. That is the whole of the company's purpose.